| Mrs Maria Eugenia Paez, | |
|
Carr #2 Km 8.2 Bo. Juan Sanchez, Bayamon, PR 00960 | |
| (787) 763-7575 | |
| Not Available |
| Full Name | Mrs Maria Eugenia Paez |
|---|---|
| Gender | Female |
| Speciality | Registered Nurse |
| Location | Carr #2 Km 8.2 Bo. Juan Sanchez, Bayamon, Puerto Rico |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1740983063 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 163W00000X | Registered Nurse | 77979 (Puerto Rico) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Mrs Maria Eugenia Paez, Po Box 607087, Bayamon, PR 00960-7087 Ph: (787) 763-7575 | Mrs Maria Eugenia Paez, Carr #2 Km 8.2 Bo. Juan Sanchez, Bayamon, PR 00960 Ph: (787) 763-7575 |
News Archive
A new study investigates how age influences SARS-CoV-2 replication, innate and adaptive immune responses.
News organizations are noting the one-year anniversary of the health law, and covering developments in the states.
TSO3 Inc. is pleased to announce that it has filed a final short form prospectus with the securities regulatory authorities in all provinces of Canada with respect to a previously announced public offering of 10,000,000 common shares for gross proceeds to the Company of C$16 million. The prospectus also qualifies for the distribution of 150,000 Common shares sold by Simon Robitaille, one of the Company's founders and Chief Scientific Officer, for gross proceeds of $240,000.
Ludwig Cancer Research scientists have developed a method to significantly improve the preclinical evaluation of chimeric antigen-receptor (CAR) T cell therapies, in which the immune system's T cells are extracted from a patient, engineered to target a specific tumor-associated molecule and then grown and reinfused for cancer treatment.
ZymoGenetics, Inc. today announced positive results from a Phase 2 clinical trial in metastatic melanoma with recombinant Interleukin 21 (IL-21) as a single agent. The trial met the primary endpoint of efficacy, as measured by objective response rate or lack of early disease progression. Overall response rate was 23.1%, in evaluable patients, and median progression-free survival was 4.3 months. The results were presented at the American Society of Clinical Oncology meeting.
› Verified 5 days ago
Vanessa Figueroa, Registered Nurse Medicare: Not Enrolled in Medicare Practice Location: 100 Ave Laurel, Bayamon, PR 00956 Phone: 787-338-8383 | |
Mailene Reyes, Registered Nurse Medicare: Not Enrolled in Medicare Practice Location: Ave. Laurel, Esq. Ave. Los Millones, Urb. Santa Juanita,, Bayamon, PR 00956 Phone: 787-995-5200 Fax: 787-787-4343 | |
Daisy Diaz Salgado, Registered Nurse Medicare: Not Enrolled in Medicare Practice Location: Programa Pitirre, Ave Laurel #100 Santa Juanita, Bayamon, PR 00956 Phone: 787-338-8383 | |
Luis Xavier Mendez, RN, BSN Registered Nurse Medicare: Not Enrolled in Medicare Practice Location: Carr. No.2 Km 8.2, Bo. Juan Sanchez, Bayamon, PR 00960 Phone: 787-763-7575 | |
Mrs. Zelideth Rivera, R.N Registered Nurse Medicare: Not Enrolled in Medicare Practice Location: Street 2 G 8, Urb.parque San Miguel, Bayamon, PR 00959 Phone: 787-949-7096 | |
Catalina Rios Pabon, RN Registered Nurse Medicare: Not Enrolled in Medicare Practice Location: Carr 167 Victory Shopping Center, Aps Clinics, Bayamon, PR 00957 Phone: 787-641-0774 Fax: 787-641-0776 | |
Mr. Omar Ortiz, CRTT, RPSGT, RN Registered Nurse Medicare: Not Enrolled in Medicare Practice Location: Reparto Valencia Calle 11, # Al-6, Bayamon, PR 00959 Phone: 787-779-3609 |